Timing of two versus three doses of quadrivalent HPV vaccine and associated effectiveness against condyloma in Sweden: a nationwide cohort study

Conclusion A two-dose schedule for qHPV vaccine with 4–7 months between the first and second doses may be as effective against condyloma in girls and women initiating vaccination under 20 years as a three-dose schedule. Results from this nationwide study support immunogenicity data from clinical trials.
Source: BMJ Open - Category: General Medicine Authors: Tags: Open access, Epidemiology Research Source Type: research

Related Links:

AbstractIn the U.S. there is an epidemic of sexually transmitted diseases (STIs). One of the most prevalent STIs is the Human Papillomavirus (HPV). Certain high risk strains of HPV are believed to cause virtually all cervical cancers, over 90% of anal cancers, 70% of oropharyngeal cancers, and the majority of anal  genital warts. HPV is preventable through vaccination and is available for both men and women. Several educational interventions have been employed, yet baseline awareness and knowledge related to HPV and 9vHPV remains relatively low among young men. What is not known is the most effective method for provid...
Source: Journal of Community Health - Category: International Medicine & Public Health Source Type: research
The Centers for Disease Control and Prevention announced Thursday it will increase the vaccination rate of its human papillomavirus by 80 percent nationwide, which could prevent 92 percent of cancers caused by HPV.
Source: Health News - UPI.com - Category: Consumer Health News Source Type: news
FRIDAY, Aug. 23, 2019 -- Ninety-two percent of human papillomavirus (HPV)-related cancers are attributable to HPV types targeted by the 9-valent HPV vaccine (9vHPV), according to research published in the Aug. 23 issue of the U.S. Centers for...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
Abstract The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination of persons aged 11-12 years to protect against certain diseases, including human papillomavirus (HPV)-associated cancers, meningococcal disease, and pertussis (1). A booster dose of quadrivalent meningococcal conjugate vaccine (MenACWY) is recommended at age 16 years, and serogroup B meningococcal vaccine (MenB) may be administered to persons aged 16-23 years (1). To estimate vaccination coverage among adolescents in the United States, CDC analyzed data from the 2018 National Immunization Survey-Teen (NIS-Teen) which in...
Source: MMWR Morb Mortal Wkl... - Category: Epidemiology Authors: Tags: MMWR Morb Mortal Wkly Rep Source Type: research
Abstract Human papillomavirus (HPV) causes nearly all cervical cancers and some cancers of the vagina, vulva, penis, anus, and oropharynx (1).* Most HPV infections are asymptomatic and clear spontaneously within 1 to 2 years; however, persistent infection with oncogenic HPV types can lead to development of precancer or cancer (2). In the United States, the 9-valent HPV vaccine (9vHPV) is available to protect against oncogenic HPV types 16, 18, 31, 33, 45, 52, and 58 as well as nononcogenic types 6 and 11 that cause genital warts. CDC analyzed data from the U.S. Cancer Statistics (USCS)† to assess the incide...
Source: MMWR Morb Mortal Wkl... - Category: Epidemiology Authors: Tags: MMWR Morb Mortal Wkly Rep Source Type: research
THURSDAY, Aug. 22, 2019 -- Coverage with the human papillomavirus (HPV) vaccine increased among boys from 2017 to 2018, according to research published in the Aug. 23 issue of the U.S. Centers for Disease Control and Prevention Morbidity and...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
To assess whether the peri-conceptional or pregnancy exposure of human papillomavirus (HPV) vaccination would increase the risk of spontaneous abortion.
Source: BMC Pregnancy and Childbirth - Category: OBGYN Authors: Tags: Research article Source Type: research
This report updates ACIP catch-up HPV vaccination recommendations and guidance published in 2014, 2015, and 2016 (1-3). Routine recommendations for vaccination of adolescents have not changed. In June 2019, ACIP recommended catch-up HPV vaccination for all persons through age 26 years. ACIP did not recommend catch-up vaccination for all adults aged 27 through 45 years, but recognized that some persons who are not adequately vaccinated might be at risk for new HPV infection and might benefit from vaccination in this age range; therefore, ACIP recommended shared clinical decision-making regarding potential HPV vaccination fo...
Source: MMWR Morb Mortal Wkl... - Category: Epidemiology Authors: Tags: MMWR Morb Mortal Wkly Rep Source Type: research
THURSDAY, Aug. 15, 2019 -- Catch-up human papillomavirus (HPV) vaccinations are recommended for all persons through age 26 years and should be considered for some persons aged 27 to 45 years, according to research published in the Aug. 16 issue of...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
For its first few years on the market, the human papillomavirus (HPV) vaccine was approved only for young girls. Over time, the U.S. Food and Drug Administration (FDA) has broadened its approval to include boys, as well as adults up to age 45—allowing more people to get the cancer-preventing vaccine, but also breeding confusion about who should get vaccinated and when. On Thursday, the U.S. Centers for Disease Control and Prevention (CDC) released new recommendations, based on guidance from the Advisory Committee on Immunization Practices, that should clear up some of that confusion. The CDC reaffirmed that its prior...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized onetime public health Source Type: news
More News: Cervical Cancer Vaccine | Clinical Trials | Epidemiology | General Medicine | Genital Warts | Girls | Human Papillomavirus (HPV) | Statistics | Study | Vaccines | Women